Oppenheimer Reiterates Outperform Rating on Tarsus Pharmaceuticals (TARS)
Tweet Send to a Friend
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $63.00 price target on Tarsus Pharmaceuticals (NASDAQ: TARS).The analyst commented: "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
